Advertisement
Advertisement
INMB
INmune Bio Inc. Common stock
2.08
USDSponsored
+0.18
+9.16%
Aug 07, 15:59 UTC -4
Closed
After-Market
2.05
-0.04
-1.68%
INMB Earnings Reports
Positive Surprise Ratio
INMB beat 18 of 30 last estimates.
60%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.20
Implied change from Q2 26 (Revenue/ EPS)
--
/+300.00%
Implied change from Q3 25 (Revenue/ EPS)
--
/-16.67%
INmune Bio Inc. Common stock earnings per share and revenue
On Aug 06, 2026, INMB reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.21 USD, resulting in a 76.28% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.16% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.20 USD, with revenue projected to reach -- USD, implying an increase of 300.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were INmune Bio Inc. Common stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, INmune Bio Inc. Common stock reported EPS of -$0.05, beating estimates by 76.28%, and revenue of $0.00, 0% as expectations.
How did the market react to INmune Bio Inc. Common stock's Q2 2026 earnings?
The stock price moved up 9.16%, changed from $1.91 before the earnings release to $2.08 the day after.
When is INmune Bio Inc. Common stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for INmune Bio Inc. Common stock's next earnings report?
Based on 6
analysts, INmune Bio Inc. Common stock is expected to report EPS of -$0.20 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement